We use cookies to see how investors use El Fondo and make its tools, data and markets better for you. You can accept or reject; essential cookies always stay on. Privacy Policy
Trades about 73% below its sector, cheaper than its peers on earnings.
Kolon Life Science Inc. is primarily engaged in the creation and distribution of pharmaceutical products and environmental materials. The company's operations are organized into two distinct units: Chemical and Bio. Its Chemical division manages both pharmaceutical activities and the development of specialty chemicals. In contrast, the Bio business unit is focused on providing contract development and manufacturing services for biopharmaceuticals. The enterprise was founded on April 21, 2000, and its corporate headquarters are situated in Seoul, South Korea.
Loading the full price history…
Run your own numbersPast performance is not a forecast.
Save 102940.KQ and get told when something moves.
Get updates
A clear, direct weekly summary.
Learn the fundamentals behind this asset.
A stock is a fraction of ownership in a real company. Buy one share and you own a piece (usually a tiny piece) of every desk, factory, contract and brand the company runs. The price moves because the market keeps revising what that whole pie is worth.
The price-to-earnings ratio is how much investors are paying for one dollar of a company's profit. A multiple, never an absolute. Always compared to something: a sector, a region, the company's own past.
Dividend yield is the annual income a stock or ETF pays out, expressed as a percentage of what you paid for it. It is the visible part of total return: the cash that lands in your account every quarter, and the lever most retail investors actually feel.
Market cap is shares times price. A simple formula that produces wildly unequal numbers: a single US tech name can be worth more than every company on a LATAM exchange combined.
